Copyright Reports & Markets. All rights reserved.

Global Biosimilar Insulin Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Biosimilar Insulin Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Biosimilar Insulin Glargine
    • 1.3.3 Biosimilar Insulin Lispro
    • 1.3.4 Other
  • 1.4 Market Analysis by Distribution Channel
    • 1.4.1 Overview: Global Biosimilar Insulin Consumption Value by Distribution Channel: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Others
  • 1.5 Global Biosimilar Insulin Market Size & Forecast
    • 1.5.1 Global Biosimilar Insulin Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Biosimilar Insulin Sales Quantity (2019-2030)
    • 1.5.3 Global Biosimilar Insulin Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Eli Lilly
    • 2.1.1 Eli Lilly Details
    • 2.1.2 Eli Lilly Major Business
    • 2.1.3 Eli Lilly Biosimilar Insulin Product and Services
    • 2.1.4 Eli Lilly Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Eli Lilly Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Biosimilar Insulin Product and Services
    • 2.2.4 Sanofi Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 Gan&Lee
    • 2.3.1 Gan&Lee Details
    • 2.3.2 Gan&Lee Major Business
    • 2.3.3 Gan&Lee Biosimilar Insulin Product and Services
    • 2.3.4 Gan&Lee Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Gan&Lee Recent Developments/Updates
  • 2.4 Tonghua Dongbao
    • 2.4.1 Tonghua Dongbao Details
    • 2.4.2 Tonghua Dongbao Major Business
    • 2.4.3 Tonghua Dongbao Biosimilar Insulin Product and Services
    • 2.4.4 Tonghua Dongbao Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Tonghua Dongbao Recent Developments/Updates
  • 2.5 United Laboratory
    • 2.5.1 United Laboratory Details
    • 2.5.2 United Laboratory Major Business
    • 2.5.3 United Laboratory Biosimilar Insulin Product and Services
    • 2.5.4 United Laboratory Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 United Laboratory Recent Developments/Updates
  • 2.6 Geropharm
    • 2.6.1 Geropharm Details
    • 2.6.2 Geropharm Major Business
    • 2.6.3 Geropharm Biosimilar Insulin Product and Services
    • 2.6.4 Geropharm Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Geropharm Recent Developments/Updates
  • 2.7 Biocon
    • 2.7.1 Biocon Details
    • 2.7.2 Biocon Major Business
    • 2.7.3 Biocon Biosimilar Insulin Product and Services
    • 2.7.4 Biocon Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Biocon Recent Developments/Updates
  • 2.8 Wockhardt
    • 2.8.1 Wockhardt Details
    • 2.8.2 Wockhardt Major Business
    • 2.8.3 Wockhardt Biosimilar Insulin Product and Services
    • 2.8.4 Wockhardt Biosimilar Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Wockhardt Recent Developments/Updates

3 Competitive Environment: Biosimilar Insulin by Manufacturer

  • 3.1 Global Biosimilar Insulin Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Biosimilar Insulin Revenue by Manufacturer (2019-2024)
  • 3.3 Global Biosimilar Insulin Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Biosimilar Insulin by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Biosimilar Insulin Manufacturer Market Share in 2023
    • 3.4.3 Top 6 Biosimilar Insulin Manufacturer Market Share in 2023
  • 3.5 Biosimilar Insulin Market: Overall Company Footprint Analysis
    • 3.5.1 Biosimilar Insulin Market: Region Footprint
    • 3.5.2 Biosimilar Insulin Market: Company Product Type Footprint
    • 3.5.3 Biosimilar Insulin Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Biosimilar Insulin Market Size by Region
    • 4.1.1 Global Biosimilar Insulin Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Biosimilar Insulin Consumption Value by Region (2019-2030)
    • 4.1.3 Global Biosimilar Insulin Average Price by Region (2019-2030)
  • 4.2 North America Biosimilar Insulin Consumption Value (2019-2030)
  • 4.3 Europe Biosimilar Insulin Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Biosimilar Insulin Consumption Value (2019-2030)
  • 4.5 South America Biosimilar Insulin Consumption Value (2019-2030)
  • 4.6 Middle East & Africa Biosimilar Insulin Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Biosimilar Insulin Sales Quantity by Type (2019-2030)
  • 5.2 Global Biosimilar Insulin Consumption Value by Type (2019-2030)
  • 5.3 Global Biosimilar Insulin Average Price by Type (2019-2030)

6 Market Segment by Distribution Channel

  • 6.1 Global Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
  • 6.2 Global Biosimilar Insulin Consumption Value by Distribution Channel (2019-2030)
  • 6.3 Global Biosimilar Insulin Average Price by Distribution Channel (2019-2030)

7 North America

  • 7.1 North America Biosimilar Insulin Sales Quantity by Type (2019-2030)
  • 7.2 North America Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
  • 7.3 North America Biosimilar Insulin Market Size by Country
    • 7.3.1 North America Biosimilar Insulin Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Biosimilar Insulin Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Biosimilar Insulin Sales Quantity by Type (2019-2030)
  • 8.2 Europe Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
  • 8.3 Europe Biosimilar Insulin Market Size by Country
    • 8.3.1 Europe Biosimilar Insulin Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Biosimilar Insulin Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Biosimilar Insulin Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
  • 9.3 Asia-Pacific Biosimilar Insulin Market Size by Region
    • 9.3.1 Asia-Pacific Biosimilar Insulin Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Biosimilar Insulin Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 South Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Biosimilar Insulin Sales Quantity by Type (2019-2030)
  • 10.2 South America Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
  • 10.3 South America Biosimilar Insulin Market Size by Country
    • 10.3.1 South America Biosimilar Insulin Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Biosimilar Insulin Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Biosimilar Insulin Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Biosimilar Insulin Sales Quantity by Distribution Channel (2019-2030)
  • 11.3 Middle East & Africa Biosimilar Insulin Market Size by Country
    • 11.3.1 Middle East & Africa Biosimilar Insulin Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Biosimilar Insulin Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Biosimilar Insulin Market Drivers
  • 12.2 Biosimilar Insulin Market Restraints
  • 12.3 Biosimilar Insulin Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Biosimilar Insulin and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Biosimilar Insulin
  • 13.3 Biosimilar Insulin Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Biosimilar Insulin Typical Distributors
  • 14.3 Biosimilar Insulin Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product"s patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
    According to our (Global Info Research) latest study, the global Biosimilar Insulin market size was valued at US$ 3038 million in 2023 and is forecast to a readjusted size of USD 7467 million by 2030 with a CAGR of 13.9% during review period.
    Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
    This report is a detailed and comprehensive analysis for global Biosimilar Insulin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Distribution Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Biosimilar Insulin market size and forecasts, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (US$/Unit), 2019-2030
    Global Biosimilar Insulin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (US$/Unit), 2019-2030
    Global Biosimilar Insulin market size and forecasts, by Type and by Distribution Channel, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (US$/Unit), 2019-2030
    Global Biosimilar Insulin market shares of main players, shipments in revenue ($ Million), sales quantity (K Unit), and ASP (US$/Unit), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Biosimilar Insulin
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Biosimilar Insulin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Biosimilar Insulin market is split by Type and by Distribution Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Distribution Channel in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Biosimilar Insulin Glargine
    Biosimilar Insulin Lispro
    Other
    Market segment by Distribution Channel
    Hospital
    Retail Pharmacy
    Others
    Major players covered
    Eli Lilly
    Sanofi
    Gan&Lee
    Tonghua Dongbao
    United Laboratory
    Geropharm
    Biocon
    Wockhardt
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Biosimilar Insulin product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Biosimilar Insulin, with price, sales quantity, revenue, and global market share of Biosimilar Insulin from 2019 to 2024.
    Chapter 3, the Biosimilar Insulin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Biosimilar Insulin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and by Distribution Channel, with sales market share and growth rate by Type, by Distribution Channel, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Biosimilar Insulin market forecast, by regions, by Type, and by Distribution Channel, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Insulin.
    Chapter 14 and 15, to describe Biosimilar Insulin sales channel, distributors, customers, research findings and conclusion.

    Buy now